Analysis of transforming growth factor-?? and profibrogenic molecules in a rat cardiac allograft model treated with cyclosporine1
- 1 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (10) , 1543-1549
- https://doi.org/10.1097/00007890-200205270-00005
Abstract
Background. Long-term treatment of heart transplantation recipients with cyclosporine (CsA) results in chronic nephrotoxic effects, which frequently lead to progressive renal failure. Transforming growth factor (TGF)-β and other fibrogenic molecules are leading candidates for these effects, because CsA is known to induce TGF-β. In this study we compared the expression of TGF-β, collagen, fibronectin, metalloproteinases, and tissue inhibitors of metalloproteinases in kidneys from recipients of heterotopic heart transplants treated with CsA for 30 and 180 days. Methods. Using a clinically relevant experimental rodent model (strain combination Wistar Furth [RT1u] into Lewis [RT1l]), heterotopic heart transplantation was performed, creating disparate cardiac allografts. The transplant study population was divided into three groups: controls and those receiving CsA immunosuppression therapy to maintain graft survival for 30-day and 180-day periods. Comparisons were made of intrarenal expression of TGF-β, collagen, fibronectin, metalloproteinase-2 (MMP-2), MMP-9, and tissue inhibitor of MMP-2, using reverse transcriptase-polymerase chain reaction. Intrarenal expression of TGF-β protein was also compared using immunochemical staining technique, and circulating levels of TGF-β protein were quantified by ELISA. Results. Intrarenal expression of TGF-β, collagen, fibronectin, MMP-2, MMP-9, and tissue inhibitor of MMP-2 was significantly increased in rats treated with CsA for 180 days compared with untreated rats and those treated for 30 days. Circulating levels and intrarenal expression of TGF-β were also significantly increased in rats treated for 180 days. Conclusion. Posttransplantation nephrotoxicity in cardiac transplant recipients treated with CsA for a long term is related to increased expression of TGF-β and other fibrogenic genes. Therapies designed to inhibit expression of TGF-β could ameliorate CsA-associated nephrotoxicity in cardiac transplant recipients.Keywords
This publication has 26 references indexed in Scilit:
- Effect of anti-transforming growth factor-βbgr; antibodies in cyclosporine-induced renal dysfunctionKidney International, 2001
- Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritisKidney International, 2001
- Renal fibrosis in mice treated with human recombinant transforming growth factor-β2Kidney International, 2000
- Renal failure after clinical heart transplantation is associated with the TGF-β1 codon 10 gene polymorphismThe Journal of Heart and Lung Transplantation, 2000
- THE RELATIONSHIP BETWEEN ACUTE REJECTION AND CHRONIC REJECTION IS HIGHLY DEPENDENT ON SPECIFIC MHC MATCHINGTransplantation, 2000
- TRANSFORMING GROWTH FACTOR (TGF)-?? MIMICS AND ANTI-TGF-?? ANTIBODY ABROGATES THE IN VIVO EFFECTS OF CYCLOSPORINETransplantation, 1999
- Matrix Metalloproteinases MMP2 and MMP9 Are Produced in Early Stages of Kidney Morphogenesis but Only MMP9 Is Required for Renal Organogenesis In VitroThe Journal of cell biology, 1997
- CYCLOSPORINE-ASSOCIATED END-STAGE NEPHROPATHY AFTER CARDIAC TRANSPLANTATIONTransplantation, 1997
- PROGRESSIVE HISTOLOGIC INJURY IN KIDNEYS FROM HEART AND LIVER TRANSPLANT RECIPIENTS RECEIVING CYCLOSPORINETransplantation, 1996
- Regulation of Alpha2(I), Alpha1(III), and Alpha2(V) Collagen mRNAs by Estradiol in the Immature Rat UterusDNA, 1988